The news roundup for the week ending 23 March 2017.
PraxisUnico challenges universities to collaborate with industry
Topics at the annual PraxisUnico conference included the Industrial Strategy Challenge Fund, international benchmarking in university venturing funds and the importance of the creative industries.
IP Group updates Touchstone offer
The updated deal values Touchstone Innovations at $590m and extends an offer to two of Touchstone’s non-executive directors to join IP Group as non-executive directors.
Cellth licenses cancer treatment technology
The technology is based on research at University of Maryland, Baltimore and University of Maryland, College Park.
Catapult Therapy TCR hits exit
TCR, a joint venture involving Imperial Innovations and UCL Business, has been acquired by Cell Medica, itself backed by Touchstone Innovations.
Changing Health focuses on $1.3m
Based on research conducted at Newcastle University, Changing Health has obtained $1.3m in a round that included North East Finance.
The immuno-oncology developer is based on research undertaken by Sophia Karagiannis at King’s College London.
Polytech Ecosystem Ventures-backed BlueFox has collected $7m in series A capital from investors including Panasonic.
FTC calls foul on DraftKings/FanDuel merger
The US Federal Trade Commission has joined two US states to seek an injunction blocking the merger of Edinburgh spinout FanDuel with DraftKings.
Concirrus connects to Touchstone for $3.8m
Touchstone Innovations has committed $3.8m for a two-tranche investment in internet of things technology developer Concirrus.
Touchstone continues to make Impression
Impression Technologies has raised $3.8m in a series B round co-led by Touchstone Innovations and Mercia Technologies.
The University of California-backed UC-RNT Fund has led a round that enabled strategic investor Axis Bank to exit.
A spinout of CEA, one of the institutes that forms part of Paris-Saclay, Kalray has developed manycore microprocessors that require only low levels of energy.
Repare constructs $68m series A
Repare Therapeutics was co-founded by researchers from Lunenfeld-Tanenbaum Research Institute, University of Toronto and New York University.
